907 research outputs found
Disclosure of investigators' Recruitment performance in multicenter clinical trials: a further step for research transparency
Transparency: A Fundamental Social Obligation for Clinical Research .After 60 years devoted to enhancing the methodology and ethics in clinical research, the last decade has been crucial to the scientific community in refining the transparency on conducting clinical trials (CTs), from their inception to the publication of results. A myriad of articles have been published on the design, conduct, conflicts of interest, reporting, and publication of CTs..
Prevalence and Progression of Ametropias in Medical Students
Background: Uncorrected refractive errors (Myopia, Hyperopia and Astigmatism) are one of the main causes of poor vision, attributing to 43% of vision deficiencies. Myopia is the most common visual disorder in the world and can progress up until the age of 20-25, when many people are in university. The etiological factors that cause myopia are still unclear and deserve to be studied. Our aim was to identify the prevalence of ametropias and self-perception of ophthalmic health in medical students at the Centro Universitário Saúde ABC/FMABC.
Methods: This is a cross-sectional study with data collected at Centro Universitário Saúde ABC/FMABC from medical students. A total of 232 students participated in the survey, from the 1st to the 4th year of study. Data was obtained through a questionnaire, which evaluates ophthalmologic health, ametropia, and self-perception.
Results: It was observed that 74.57% of the students had some type of ametropia, myopia being the most recurrent (59.05%). The study shows significant data of an increase in the grade of students from 1st to 4th grade throughout college. It was observed that the average daily study time of the students was 9.68 hours and abuse in the use of electronic devices.
Conclusion: This study presented a high prevalence of ametropias among medical students at the Centro Universitário ABC/FMABC, in addition to a high prevalence of multifactorial myopia and an increased need to update their diopters (degrees) during the course of university
Global timber investments, 2005 to 2017
We estimated timber investment returns for 22 countries and 54 species/management regimes in 2017, for a range of global timber plantation species and countries at the stand level, using capital budgeting criteria, without land costs, at a real discount rate of 8%. Returns were estimated for the principal plantation countries in the Americas-Brazil, Argentina, Uruguay, Chile, Colombia, Venezuela, Paraguay, Mexico, and the United States-as well as New Zealand, Australia, South Africa, China, Vietnam, Laos, Spain, Finland, Poland, Scotland, and France. South American plantation growth rates and their concomitant returns were generally greater, at more than 12% Internal Rates of Return (IRRs), as were those in China, Vietnam, and Laos. These IRRs were followed by those for plantations in southern hemisphere countries of Australia and New Zealand and in Mexico, with IRRs around 8%. Temperate forest plantations in the U.S. and Europe returned less, from 4% to 8%, but those countries have less financial risk, better timber markets, and more infrastructure. Returns to most planted species in all countries except Asia have decreased from 2005 to 2017. If land costs were included in calculating the overall timberland investment returns, the IRRs would decrease from 3 percentage points less for loblolly pine in the U.S. South to 8 percentage points less for eucalypts in Brazil.Peer reviewe
Better post-operative prediction and management of chronic pain in adults after total knee replacement:the multidisciplinary STAR research programme including RCT
Background: The treatment of osteoarthritis with knee replacement aims to reduce pain and disability.
However, some people experience chronic pain.
Objectives: To improve outcomes for people with chronic pain after knee replacement by identifying
post-surgical predictors and effective interventions, characterising patient pathways and resource use,
developing and evaluating a new care pathway, and exploring non-use of services.
Design: The programme comprised systematic reviews, national database analyses, a cohort study,
intervention development, a randomised controlled trial, health economic analyses, qualitative studies
and stakeholder engagement. Extensive and meaningful patient and public involvement underpinned all
studies.
Setting: NHS, secondary care, primary care.
Participants: People with, or at risk of, chronic pain after knee replacement and health-care
professionals involved in the care of people with pain.
Interventions: A care pathway for the management of people with pain at 3 months after knee
replacement.
Main outcome measures: Patient-reported outcomes and cost-effectiveness over 12 months.
Data sources: Literature databases, the National Joint Registry, Hospital Episode Statistics, patient-
reported outcomes, the Clinical Practice Research Datalink, the Clinical Outcomes in Arthroplasty Study,
the Support and Treatment After joint Replacement randomised trial, interviews with 90 patients and 14
health-care professionals, and stakeholder events.
Review methods: Systematic reviews of cohort studies or randomised trials, using meta-analysis or
narrative synthesis.
Results: In the Clinical Outcomes in Arthroplasty Study cohort, 14% of people experienced chronic pain 1
year after knee replacement. By 5 years, 65% reported no pain, 31% fluctuated and 4% remained in chronic
pain. People with chronic pain had a worse quality of life, higher primary care costs, and more frequent
analgesia prescriptions, particularly for opioids, than those not in chronic pain. People with chronic pain after
knee replacement who made little or no use of services often felt nothing more could be done, or that further
treatments may have no benefit or cause harm. People described a feeling of disconnection from their
replaced knee. Analysis of UK databases identified risk factors for chronic pain after knee replacement. Pre-
operative predictors were mild knee pain, smoking, deprivation, body mass index between 35 and 40 kg/m2
and knee arthroscopy. Peri- and post-operative predictors were mechanical complications, infection,
readmission, revision, extended hospital stay, manipulation under anaesthetic and use of opioids or
antidepressants. In systematic reviews, pre-operative exercise and education showed no benefit in relation
to chronic pain. Peri-operative interventions that merit further research were identified. Common peri-
operative treatments were not associated with chronic pain. There was no strong evidence favouring specific
post-operative physiotherapy content. We evaluated the Support and Treatment After joint Replacement
care pathway in a multicentre randomised controlled trial. We randomised 363 people with pain at 3 months
after knee replacement from eight NHS Trusts in England and Wales. At 12 months’ follow-up, the
intervention group had lower mean pain severity (adjusted difference –0.65, 95% confidence interval –1.17
to -0.13; p = 0.014) and pain interference (adjusted difference –0.68, 95% confidence interval –1.29 to -0.08;
p = 0.026), as measured on the Brief Pain Inventory subscales (scale 0–10). People receiving the Support and
Treatment After joint Replacement pathway had lower NHS and Personal Social Services costs (–£724, 95%
confidence interval –£150 to £51) and higher quality-adjusted life-years (0.03, 95% confidence interval
–0.008 to 0.06) than those with usual care. The Support and Treatment After joint Replacement pathway
was cost-effective with an incremental net monetary benefit at the £20,000 per quality-adjusted life-year
threshold of £1256 (95% confidence interval £164 to £2348), indicating a 98.79% probability that the
intervention is the cost-effective option. Participants found the Support and Treatment After joint
Replacement pathway acceptable, with opportunities to receive information and discuss concerns while
ensuring further treatment and support. In systematic reviews considering treatments for chronic pain after
surgery we identified some unifactorial interventions that merit further research after knee replacement.
Health-care professionals delivering and implementing the Support and Treatment After joint Replacement
pathway valued its focus on neuropathic pain and psychosocial issues, enhanced patient care, formalised
referrals, and improved pain management. Stakeholders supported pathway implementation.
Limitations: Database analyses were limited to factors recorded in data sets. Pain was only measured 6
months after surgery. However, analyses including large numbers of centres and patients should be
generalisable across the NHS. In many studies found in systematic reviews, long-term pain was not a key
outcome.
Conclusions: The Support and Treatment After joint Replacement pathway is a clinically effective and
cost-effective, acceptable intervention for the management of chronic pain after knee replacement.
Unifactorial interventions merit further study before inclusion in patient care. People with pain should
be empowered to seek health care, with the support of health-care professionals.
Future work: Future work should include research relating to the implementation of the Support and
Treatment After joint Replacement pathway into the NHS, an assessment of its long-term clinical
effectiveness and cost-effectiveness and wider application, and an evaluation of new interventions for
incorporation in the pathway. It will also be important to design and conduct research to improve
communication between patients and health-care professionals before surgery; explore whether or not
education and support can enable earlier recognition of chronic pain; consider research that may identify
how to support people’s feelings of disconnectedness from their new knee; and design and evaluate a
pre-surgical intervention based on risk factors.
Study registration: All systematic reviews were registered on PROSPERO (CRD42015015957,
CRD42016041374 and CRD42017041382). The Support and Treatment After joint Replacement
randomised trial was registered as ISRCTN92545361.
Funding: This project was funded by the National Institute for Health and Care Research (NIHR)
Programme Grants for Applied Research programme and will be published in full in Programme Grants for
Applied Research; Vol. 11, No. 3. See the NIHR Journals Library website for further project information
The Astropy Problem
The Astropy Project (http://astropy.org) is, in its own words, "a community
effort to develop a single core package for Astronomy in Python and foster
interoperability between Python astronomy packages." For five years this
project has been managed, written, and operated as a grassroots,
self-organized, almost entirely volunteer effort while the software is used by
the majority of the astronomical community. Despite this, the project has
always been and remains to this day effectively unfunded. Further, contributors
receive little or no formal recognition for creating and supporting what is now
critical software. This paper explores the problem in detail, outlines possible
solutions to correct this, and presents a few suggestions on how to address the
sustainability of general purpose astronomical software
Recommended from our members
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Background: Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). Objectives: A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C independently predicted major adverse cardiovascular events (MACE). Methods: One to 12 months after ACS, 18,924 patients on high-intensity statin therapy were randomized to alirocumab or placebo and followed for 2.8 years (median). Lipoprotein(a) was measured at randomization and 4 and 12 months thereafter. The primary MACE outcome was coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina. Results: Baseline lipoprotein(a) levels (median: 21.2 mg/dl; interquartile range [IQR]: 6.7 to 59.6 mg/dl) and LDL-C [corrected for cholesterol content in lipoprotein(a)] predicted MACE. Alirocumab reduced lipoprotein(a) by 5.0 mg/dl (IQR: 0 to 13.5 mg/dl), corrected LDL-C by 51.1 mg/dl (IQR: 33.7 to 67.2 mg/dl), and reduced the risk of MACE (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.78 to 0.93). Alirocumab-induced reductions of lipoprotein(a) and corrected LDL-C independently predicted lower risk of MACE, after adjustment for baseline concentrations of both lipoproteins and demographic and clinical characteristics. A 1-mg/dl reduction in lipoprotein(a) with alirocumab was associated with a HR of 0.994 (95% CI: 0.990 to 0.999; p = 0.0081). Conclusions: Baseline lipoprotein(a) and corrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS. Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction, which suggests that lipoprotein(a) should be an independent treatment target after ACS. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402)
Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis
BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London
GTC Follow-up Observations of Very Metal-Poor Star Candidates from DESI
The observations from the Dark Energy Spectroscopic Instrument (DESI) will
significantly increase the numbers of known extremely metal-poor stars by a
factor of ~ 10, improving the sample statistics to study the early chemical
evolution of the Milky Way and the nature of the first stars. In this paper we
report high signal-to-noise follow-up observations of 9 metal-poor stars
identified during the DESI commissioning with the Optical System for Imaging
and low-Intermediate-Resolution Integrated Spectroscopy (OSIRIS) instrument on
the 10.4m Gran Telescopio Canarias (GTC). The analysis of the data using a
well-vetted methodology confirms the quality of the DESI spectra and the
performance of the pipelines developed for the data reduction and analysis of
DESI data.Comment: 13 pages, 4 figures, to be submitted to ApJ, data available from
https://doi.org/10.5281/zenodo.802084
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
BACKGROUND: Cholesterol reduction with proprotein convertase subtilisin-kexin type 9 inhibitors reduces ischemic events; however, the cost-effectiveness in statin-treated patients with recent acute coronary syndrome remains uncertain. OBJECTIVES: This study sought to determine whether further cholesterol reduction with alirocumab would be cost-effective in patients with a recent acute coronary syndrome on optimal statin therapy. METHODS: A cost-effectiveness model leveraging patient-level data from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was developed to estimate costs and outcomes over a lifetime horizon. Patients (n = 18,924) had a recent acute coronary syndrome and were on high-intensity or maximum-tolerated statin therapy, with a baseline low-density lipoprotein cholesterol (LDL-C) level ?70 mg/dl, non-high-density lipoprotein cholesterol ?100 mg/dl, or apolipoprotein B ?80 mg/l. Alirocumab 75 mg or placebo was administered subcutaneously every 2 weeks. Alirocumab was blindly titrated to 150 mg if LDL-C remained ?50 mg/dl or switched to placebo if 2 consecutive LDL-C levels were <15 mg/dl. Incremental cost per quality-adjusted life-year (QALY) was determined with the addition of alirocumab versus placebo and, based on clinical efficacy findings from the trial, was stratified by baseline LDL-C levels ?100 mg/dl and <100 mg/dl. RESULTS: Across the overall population recruited to the ODYSSEY OUTCOMES trial, using an annual treatment cost of US92,200 per QALY (base case). The cost was US299,400. Among patients with LDL-C ?100 mg/dl, incremental cost-effectiveness ratios remained below US$100,000 per QALY across a wide variety of sensitivity analyses. CONCLUSIONS: In patients with a recent acute coronary syndrome on optimal statin therapy, alirocumab improves cardiovascular outcomes at costs considered intermediate value, with good value in patients with baseline LDL-C ?100 mg/dl but less economic value with LDL-C <100 mg/dl. (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]; NCT01663402)
- …